Antonia SJ, López -Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small- cell lung cancer (CheckMate 032): a multicentre, open -label, phase 1/2 trial. The Lancet Oncology;17:883-95.